Wang, Chang https://orcid.org/0009-0005-1630-9453
Xue, Yonger https://orcid.org/0000-0002-6022-2487
Markovic, Tamara
Li, Haoyuan
Wang, Siyu
Zhong, Yichen https://orcid.org/0000-0003-3652-1257
Du, Shi
Zhang, Yuebao https://orcid.org/0009-0000-7883-1937
Hou, Xucheng https://orcid.org/0000-0001-7833-8704
Yu, Yang https://orcid.org/0000-0001-6885-019X
Liu, Zhengwei https://orcid.org/0009-0003-5105-6709
Tian, Meng https://orcid.org/0000-0001-7719-9896
Kang, Diana D.
Wang, Leiming
Guo, Kaiyuan https://orcid.org/0009-0001-0621-9543
Cao, Dinglingge
Yan, Jingyue
Deng, Binbin
McComb, David W. https://orcid.org/0000-0003-3763-9652
Parsons, Ramon E.
Minier-Toribio, Angelica M. https://orcid.org/0000-0002-8860-5973
Holt, Leanne M.
Pan, Jiayi
Hashemi, Alice
Kopell, Brian H. https://orcid.org/0000-0002-6955-4787
Charney, Alexander W. https://orcid.org/0000-0001-8135-6858
Nestler, Eric J. https://orcid.org/0000-0002-7905-2000
Peng, Paul C. https://orcid.org/0009-0006-7801-4738
Dong, Yizhou https://orcid.org/0000-0001-5786-0659
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R35GM144117)
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (P01DA047233)
Article History
Received: 15 June 2023
Accepted: 20 December 2024
First Online: 17 February 2025
Competing interests
: Y.D. is a scientific advisor in Arbor Biotechnologies, Sirnagen Therapeutics and Moonwalk Biosciences, and also a co-founder and holds equity in Immunanoengineering Therapeutics. J.P. is a current employee of Biogen with salary and stock options. P.C.P. is a current employee of City Therapeutics with salary and stock options. The other authors declare no competing interests.